PET2-Adapted Therapy in Patients With Advanced-Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater

被引：0
|
作者：
Pinto, Antonio [1 ]
Cuccaro, Annarosa [1 ]
Bonanni, Matteo [1 ]
Fresa, Alberto [1 ]
Filippi, Rosaria De [2 ]
Corazzelli, Gaetano [1 ]
机构：
[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Hematol Oncol & Stem Cell Transplantat Unit, Naples, Italy
[2] Univ Federico II, Dept Clin Med & Surg, Naples, Italy
来源：
HEMATOLOGICAL ONCOLOGY | 2025年 / 43卷 / 01期
关键词：
ABVD; Hodgkin lymphoma; iPET2; therapy escalation/de-escalation; FOLLOW-UP; ESCALATED-BEACOPP; OPEN-LABEL; PHASE-II; CHEMOTHERAPY;
D O I：
10.1002/hon.70004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Cost-Effectiveness of Interim PET Response Adapted Therapy In ABVD-Treated, Advanced-Stage Hodgkin Lymphoma
    Gallamini, Andrea
    Marchetti, Monia
    Borra, Anna
    Sorasio, Roberto
    Fiore, Francesca
    BLOOD, 2011, 118 (21) : 679 - 680
  • [2] Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
    Gallamini, A.
    Kostakoglu, L.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1045 - 1047
  • [3] Risk-adapted therapy for advanced-stage Hodgkin lymphoma
    Spinner, Michael A.
    Advani, Ranjana H.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 200 - 206
  • [4] Early interim FDG-PET overshadows the prognostic role of IPS in advanced-stage Hodgkin lymphoma treated by conventional ABVD therapy
    Gallamini, A.
    Hutchings, M.
    Rigacci, L.
    Specht, L.
    Merli, F.
    Hansen, M.
    Patti, C.
    Loft, A.
    Di Raimondo, F.
    D'Amore, F.
    Biggi, A.
    Vitolo, U.
    Stelitano, C.
    Sancetta, R.
    Trentin, L.
    Luminari, S.
    Iannitto, E.
    Viviani, S.
    Pierri, I.
    Levis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 32 - 32
  • [5] The prognostic value of the tumor/microenvironment signature compared to early pet scan in advanced-stage, ABVD-treated Hodgkin lymphoma patients
    Gallamini, A.
    Agostinelli, C.
    Rigacci, L.
    D'Amore, F.
    Merli, F.
    Zinzani, P.
    Vitolo, U.
    Patti, C.
    Stelitano, C.
    Di Raimondo, F.
    Levis, A.
    Trentin, L.
    Chisesi, T.
    Kamper, P.
    Pileri, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [6] Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
    Ansell, Stephen M.
    Connors, Joseph M.
    Park, Steven I.
    O'Meara, Megan M.
    Younes, Anas
    BLOOD, 2012, 120 (21)
  • [7] Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
    Younes, Anas
    Connors, Joseph M.
    Park, Steven I.
    Hunder, Naomi N. H.
    Ansell, Stephen M.
    BLOOD, 2011, 118 (21) : 436 - 437
  • [8] Radiation Therapy for Advanced-Stage Hodgkin Lymphoma
    Lockney, Natalie A.
    Yang, Joanna C.
    ADVANCES IN RADIATION ONCOLOGY, 2020, 5 (05) : 809 - 816
  • [9] Optimizing therapy in advanced-stage Hodgkin lymphoma
    Lim, Sean H.
    Johnson, Peter W. M.
    BLOOD, 2018, 131 (15) : 1679 - 1688
  • [10] EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE, ADVANCED-STAGE, ABVD-TREATED HODGKIN LYMPHOMA PATIENTS
    Fiore, F.
    Patti, K.
    Viviani, S.
    Rossi, A.
    Di Raimondo, F.
    Cantonetti, M.
    Stelitano, C.
    Feldman, T.
    Gavarotti, P.
    Sorasio, R.
    Biggi, A.
    Barrington, S.
    Gallamini, A.
    HAEMATOLOGICA, 2010, 95 : S22 - S22
12345